38 results about "Xanthine oxidase activity" patented technology

The invention discloses a hexapeptide TE6 with xanthine oxidase inhibitory activity and a preparation method and application thereof, and belongs to the technical field of small molecule peptides. The amino acid sequence of the hexapeptide TE6 is TIATVE, and the hexapeptide TE6 can be prepared through a solid-phase synthesis method and an enzymolysis method. The hexapeptide TE6 is identified from a solieria cavaleriei proteolysis solution and has potential interaction with xanthine oxidase, under the concentration of 0.1 mg / mL, the xanthine oxidase inhibition rate is 44.74%, and compared with goose carnosine (the xanthine oxidase inhibition rate is 36.03%), the xanthine oxidase inhibition rate is remarkably increased (plt; 0.05), which is stronger in xanthine oxidase inhibitory activity, and can be used for preparing a preparation for inhibiting xanthine oxidase activity and relieving hyperuricemia.

The application discloses application of total flavones of chrysanthemum morifolium ramat and metabolites thereof in preparation of uric acid-lowering or liver and kidney protecting drugs or health care products. The total flavones of chrysanthemum morifolium ramat contain various flavone compounds. In a hyperuricemia model mouse, the total flavones of chrysanthemum morifolium ramat can significantly reduce blood uric acid level, and has a significant protective effect on liver and kidney, and the effect is achieved by inhibiting the activity and expression of xanthine oxidase and adenosine deaminase in the liver, and regulating the expression of uric acid related transporters in the kidney. Meanwhile, metabolites of the total flavones of chrysanthemum morifolium ramat, luteolin-7-O-glucuronide and apigenin-7-O-glucuronide, can also play a pharmacological role in the mouse body. In vitro experiments and mouse primary hepatocytes further prove that luteolin-7-O-glucuronide and apigenin-7-O-glucuronide have an inhibiting effect on the activity and expression level of xanthine oxidase. The application widens the application range of traditional Chinese medicinal materials, and provides a new direction for development of efficient and low-toxic uric acid-lowering and anti-gout drugs or health care products.

The invention discloses a preparation method of hippocampus oil, which comprises the following steps: 1) adding dried hippocampus powder into a dichloromethane-methanol mixed solution, uniformly stirring, and extracting for 24 hours; 2) filtering the leach liquor, adding water, fully and uniformly mixing, standing for 12 hours, and collecting a lower layer organic phase; 3, the organic phase is subjected to rotary evaporation drying.The invention further discloses application of the hippocampus oil in preparation of uric acid lowering products.The hippocampus oil is rich in omega-3 polyunsaturated fatty acid (EPA and DHA), the activity of xanthine oxidase is moderately reduced, release of inflammatory factors is inhibited, and the comprehensive effect of inhibiting generation and relieving inflammation is achieved.

The invention provides a medicinal and edible tea drink composition for assisting in reducing uric acid and a preparation method thereof, and belongs to the technical field of health-care food. The medicinal and edible tea drink composition for assisting in reducing uric acid comprises corn stigma, chicory, folium mori, fructus gardeniae, radix puerariae, fructus crataegi, semen coicis, poria cocos, rhizoma polygonati, pericarpium citri reticulatae and liquorice root. Cichorium intybus and folium mori are used as monarch drugs and synergistically inhibit the activity of xanthine oxidase; corn stigma and cape jasmine are used as ministerial drugs and have the effects of forcefully inducing diuresis and reducing the blood uric The radix puerariae can improve insulin resistance, the coix seeds and the poria cocos can tonify spleen and excrete dampness, and the rhizoma polygonati can tonify spleen and tonify kidney to treat both symptoms and root causes and serve as Hawthorn, pericarpium citri reticulatae and liquorice are used for regulating the medicine property and neutralizing the bitter taste, so that the consumer experience and compliance are greatly improved. The medicinal and edible tea drink composition achieves the effect of reducing uric acid through a multi-target and multi-path synergistic effect of inhibiting generation, promoting excretion and conditioning root.

The invention discloses a preparation method of an astragalus extract with a uric acid reducing effect, and belongs to the technical field of biological medicines. The method comprises the following steps: concentrating an ethanol extract of radix astragali, extracting by using n-butyl alcohol, ethyl acetate and petroleum ether respectively, and concentrating an extract to obtain n-butyl alcohol, ethyl acetate and petroleum ether extraction parts and residual parts respectively, so as to obtain an n-butyl alcohol extract, namely the radix astragali extract for reducing uric acid. Efficacy experiments show that the normal butanol extraction part of the ethanol extract of the astragalus membranaceus can obviously reduce the serum uric acid level (SUA) of a mouse with hyperuricemia, inhibit the activity of xanthine oxidase (XOD) and effectively improve kidney injury caused by the hyperuricemia. The uric acid reducing effect of the radix astragali n-butyl alcohol extract is close to that of a clinical drug allopurinol, and the radix astragali n-butyl alcohol extract has wide development and application prospects in the aspect of relieving hyperuricemia.

The application discloses a South China Sea Decapterus maruadsi polypeptide with uric acid reducing and antioxidant activities and an application thereof, and relates to the technical field of biology. The polypeptide with high uric acid reducing activity and antioxidant activity is screened through activity prediction and molecular docking, and the amino acid sequence is FYDWWK. The polypeptide can be stably combined with the active center of xanthine oxidase, forms multiple hydrogen bonds and hydrophobic interaction, significantly inhibits the generation of uric acid, and has an in-vitro xanthine oxidase inhibition IC 50 of 3.068±0.2547 mmol / L. Meanwhile, the polypeptide has excellent DPPH free radical scavenging capacity, and an IC 50 of 5.033±0.5476 mmol / L. The polypeptide has good stability, still has high efficient inhibitory activity after simulated gastrointestinal digestion, and has oral development potential. The polypeptide is a natural marine small molecule active peptide, is safe and easy to absorb, and can be applied to the preparation of products related to uric acid reducing and / or antioxidant.

The present application provides a compound having a structure shown in Formula I, II or III or its enantiomer, diastereoisomer, racemate, stereoisomer, geometric isomer, nitroxide, metabolite or its pharmaceutically acceptable salt, ester, solvate, hydrate, isotopically labeled compound or prodrug. The non-fenofibrate 4-position ether derivative of the present application has an excellent xanthine oxidase activity inhibitory activity.

The application discloses a polypeptide with uric acid reducing activity and a preparation method and application thereof, relates to the field of bioactive peptides, and provides a preparation method of the polypeptide with uric acid reducing activity, which takes whey protein as raw material, and obtains the polypeptide with high activity through directional enzymolysis and ultrafiltration purification, and the polypeptide can reduce blood uric acid level by inhibiting xanthine oxidase activity, and the method has the advantages of high efficiency, low cost and easy implementation, can be implemented on a large scale, and is helpful to improving the utilization value of whey protein in the industry, and provides a new way for the development of functional natural anti-uric acid level abnormality or xanthine oxidase activity abnormality related disease products.

The application discloses a yak milk casein peptide with uric acid reducing activity and application thereof, and belongs to the technical field of protein peptide development. The yak milk casein peptide with clear uric acid reducing activity is prepared by taking yak milk casein as raw material, and the yak milk casein peptide can inhibit xanthine oxidase activity, reduce uric acid generation, and has good anti-inflammatory activity. The yak milk casein peptide is rich in small molecule active peptides, can be directly absorbed and utilized by the body, has excellent bioavailability, and has good application potential in improving hyperuricemia and related inflammatory damage. The application provides a new raw material source for developing hyperuricemia conditioning functional food and auxiliary intervention.

The invention discloses an application of parabacteroides dieldrii in preparation of a product for treating hyperuricemia. The activity of xanthine oxidase is inhibited through the parabacteroides dieldrii, uric acid related transporters are changed, and damaged organs are protected to play a uric acid reducing effect, so that chronic hyperuricemia is improved. In vitro, the parabacteroides dieldrii can inhibit the activity of xanthine oxidase. On the animal level, the parabacteroides dielsii can relieve liver and kidney injuries caused by hyperuricemia and can repair the injured intestinal barrier at the same time. Therefore, a design thought can be provided for an intestinal flora uric acid reducing preparation, so that a new intestinal flora target is provided for clinical treatment of hyperuricemia. According to the present invention, the activity of xanthine oxidase is inhibited in vitro, the uric acid transporter URAT1 in the kidney is reduced in vivo, the uric acid excretion transporter ABCG2 is increased, and the liver and kidney injury and the intestinal barrier damage caused by hyperuricemia are relieved so as to reduce the serum uric acid level and improve the hyperuricemia;

The present application belongs to the technical field of bioactive peptides, functional food and biological medicine, and particularly relates to a marine fish-derived xanthine oxidase inhibiting heptapeptide NPLVTPP and its application in reducing uric acid. The present application discloses a marine fish-derived heptapeptide NPLVTPP with xanthine oxidase inhibiting activity, and the amino acid sequence of the heptapeptide is Asn-Pro-Leu-Val-Thr-Pro-Pro. The heptapeptide can be prepared by solid-phase chemical synthesis or marine fish protein enzymatic separation and purification, can significantly inhibit xanthine oxidase activity, reduce uric acid generation, can effectively reduce serum uric acid level in a hyperuricemia animal model, and can improve high uric acid related kidney function damage. The present application also protects the application of the heptapeptide in preparing xanthine oxidase inhibitors, uric acid reducing products, products for preventing or improving hyperuricemia and kidney damage, and a medicine, food or nutritional composition containing the heptapeptide. The polypeptide sequence of the present application is clear, the target is clear, the in vivo and in vitro efficacy is clear, the source is safe, and the polypeptide can be used in the fields of functional food and biological medicine.

To provide effective and safe gout-ameliorating agents and compositions, effective and safe hepatic function-improving agents and compositions, effective and safe immunostimulating agents and compositions, effective and safe anti-aging agents and compositions, effective and safe anti-inflammatory agents and compositions, effective and safe hair tonic agents and compositions, and effective and safe antioxidative agents and compositions.SOLUTION: The invention provides a gout-ameliorating agent, hepatic function improving agent, antiaging agent, anti-inflammatory agent, hair tonic agent or antioxidative agent each comprising a Peucedanum japonicum extract.SELECTED DRAWING: None

The invention discloses a pentapeptide VE5 with xanthine oxidase inhibitory activity and a preparation method and application thereof, and belongs to the technical field of small molecule peptides. The amino acid sequence of the pentapeptide VE5 is VSIVE, and the pentapeptide VE5 can be prepared through a solid-phase synthesis method and an enzymolysis method. The pentapeptide VE5 is identified from porphyra haitanensis proteolysis liquid and has potential interaction with xanthine oxidase, under the concentration of 0.1 mg / mL, the xanthine oxidase inhibition rate is 67.88%, and compared with goose carnosine (the xanthine oxidase inhibition rate is 36.03%), the xanthine oxidase inhibition rate is remarkably increased (plt; and the compound has higher xanthine oxidase inhibitory activity, and can be used for preparing a preparation for inhibiting xanthine oxidase activity and relieving hyperuricemia.

The application discloses a bird's nest peptide for inhibiting xanthine oxidase and application thereof, and belongs to the technical field of functional polypeptides. The amino acid sequence of the bird's nest peptide for inhibiting xanthine oxidase is WGLL, can chelate an active center of xanthine oxidase (XOD), and is helpful for inhibiting the activity of XOD in catalyzing conversion of xanthine or hypoxanthine. The application further provides a bird's nest peptide powder containing the bird's nest peptide for inhibiting xanthine oxidase. The bird's nest peptide powder can significantly reduce the rate of conversion of xanthine or hypoxanthine into uric acid catalyzed by XOD, has good uric acid reducing effect, can be applied to development of uric acid reducing products or various uric acid reducing products, and has high market value.

The present application relates to the field of biotechnology, in particular to astaxanthin and dihydroquercetin co-loaded liposome and its application in preparation of uric acid-lowering products. According to the steps of "in vitro function screening - optimal ratio determination - co-loaded liposome construction - surface coating and stabilization treatment - uric acid-lowering application verification", the obtained system is verified through physicochemical characterization, stability test and animal experiment. The results show that the co-loaded liposome can reduce the serum uric acid level of high uric acid model mice, inhibit the activity of liver xanthine oxidase, and improve the related indexes of kidney function and histopathological damage.

The application discloses a preparation method of hippocampus oil, which comprises the following steps: 1) adding hippocampus dry powder into dichloromethane-methanol mixed solution and stirring uniformly, and then leaching for 24 hours; 2) after filtering the leaching solution, adding water and mixing fully, and then standing for 12 hours, and then collecting the lower organic phase; and 3) performing rotary evaporation and drying on the organic phase. The application further discloses the use of the hippocampus oil in the preparation of a product for reducing uric acid. The hippocampus oil is rich in omega-3 polyunsaturated fatty acids (EPA and DHA), shows moderate down-regulation on xanthine oxidase activity and inhibition on the release of inflammatory factors, and achieves the comprehensive effect of 'inhibiting generation and relieving inflammation'.

The invention discloses lactobacillus fermentum HF17 capable of inhibiting xanthine oxidase activity and application of the lactobacillus fermentum HF17. The lactobacillus fermentum HF17 is lactobacillus fermentum and is preserved in the China Center for Type Culture Collection (CCTCC), and the lactobacillus fermentum HF17 is preserved in the China Center for Type Culture Collection (CCTCC). The preservation number of the strain is CCTCC (China Center For Type Culture Collection) Animal experiments show that the strain has the function of inhibiting the activity of xanthine oxidase to reduce uric acid, and lactobacillus fermentum HF17 reduces gene expression of purine metabolism related enzymes in the liver through mediation to inhibit synthesis of uric acid; according to the present invention, the gene expression of the uric acid secretion transporter in the kidney is up-regulated, the gene expression of the uric acid resorption transporter is down-regulated, and the excretion of uric acid in the mouse body is promoted so as to improve the uric acid level of the hyperuricemia mouse, improve the species richness and diversity of the intestinal flora, and improve the hyperuricemia-related metabolic disorder and other phenomena;

The present invention relates to a composite probiotic formulation for alleviating hyperuricemia and use thereof. Strains in the composite probiotic formulation for alleviating hyperuricemia comprise Bifidobacterium animalis subsp. lactis BLa80 strain with a deposit number of CGMCC No. 15410, Lacticaseibacillus rhamnosus LRa05 strain with a deposit number of CGMCC No. 1.12734, and Bifidobacterium breve BBr60 strain with a deposit number of CGMCC No. 12915. The three strains can cooperate with each other and promote each other, and have a synergistic effect in the aspect of alleviating hyperuricemia, which is specifically manifested in: alleviating the phenomenon of uric acid elevation caused by hyperuricemia, reducing xanthine oxidase activity, and lowering serum uric acid nitrogen levels.

The application discloses a one-pot extraction method of a Gynura divaricata compound composition and application of the Gynura divaricata compound composition in reducing uric acid, and the Gynura divaricata, sophora flower and galangal are crushed, and are weighed and uniformly mixed according to proportions; the mixture is fully extracted by using an ultrasonic-assisted ethanol extraction method, and a filtrate is obtained by filtration; the filtrate is concentrated by a rotary evaporator under reduced pressure until no alcohol taste is left, an appropriate amount of distilled water is added, and a concentrated solution is obtained; the concentrated solution is freeze-dried, and is stored in a desiccator to obtain the Gynura divaricata compound composition. The Gynura divaricata compound composition prepared by the application has the advantages of simple and rapid preparation process, low cost, high yield, good inhibition activity on xanthine oxidase, and higher inhibition rate on xanthine oxidase activity than a separately extracted and compounded composition, and is expected to be applied to preparation of a xanthine oxidase inhibiting uric acid reducing drug.

The invention provides an application of pithecellobium clypearia, and discloses an application of 7-galloyl telicolor flavane in resisting inflammation, inhibiting xanthine oxidase activity and treating hyperuricemia related diseases for the first time. Through enzyme inhibition tests, molecular docking and molecular dynamics simulation, the inhibition effect and the action mechanism of the 7-galloyl tericolor flavane on the activity of xanthine oxidase are discussed, the 7-galloyl tericolor flavane has excellent xanthine oxidase inhibition activity, and the half inhibitory concentration IC50 value of the 7-galloyl tericolor flavane is 6.75 + / -0.67 mu M. Experiments prove that the 7-galloyl telicolor flavane can remarkably reduce the serum uric acid level of a hyperuricemia mouse model, can reduce the oxidative stress level of a mouse, protects liver and kidney from being damaged during oxidative stress, and shows that the 7-galloyl telicolor flavane can be used for treating kidney injury caused by uric acid, and has a good application prospect. The compound has potential application value in the aspects of anti-gout drugs, anti-hyperuricemia drugs and the like.

The application discloses a composition with a function of reducing uric acid and a preparation process thereof, which is prepared from the following raw materials in parts by weight: 10-30 parts of chicory, 5-20 parts of gardenia, 5-15 parts of mulberry leaves, 5-15 parts of radix puerariae, 10-20 parts of coix seed, 5-15 parts of poria cocos, and 2-8 parts of licorice root. The application has the beneficial effects that: the seven kinds of medicine and food homologous medicinal materials such as chicory and gardenia are scientifically matched, uric acid is reduced through the double ways of inhibiting xanthine oxidase activity and promoting uric acid excretion, the animal experiment shows that the effect is better than that of the positive drug allopurinol, and the safety is high, and there is no toxic side effect; the preparation process is simple, there is no organic solvent residue, various oral dosage forms can be prepared, and the application is suitable for the auxiliary conditioning of hyperuricemia and gout.

The application discloses a pentapeptide LE5 with xanthine oxidase inhibiting activity and a preparation method and application thereof, and belongs to the technical field of small-molecule peptides. The amino acid sequence of the pentapeptide LE5 is LGGVE, and the pentapeptide LE5 can be prepared by a solid-phase synthesis method and an enzymolysis method. The pentapeptide LE5 is identified from a Gracilaria lemaneiformis protein enzymolysis liquid, has potential interaction with xanthine oxidase, and has an xanthine oxidase inhibition rate of 60.58% at a concentration of 0.1 mg / mL. Compared with an anserine (xanthine oxidase inhibition rate of 36.03%), the xanthine oxidase inhibition rate is extremely significantly increased (p<0.001), and the xanthine oxidase inhibiting activity is stronger, so that the pentapeptide LE5 can be used for preparing an xanthine oxidase activity inhibiting preparation and relieving hyperuricemia.

The invention relates to the technical field of microbial fermentation, in particular to a preparation method and application of a fermented papaya extract. The fermented papaya extract is prepared by taking water and a papaya extract as main base materials, and adding lactobacillus rhamnosus LR.M8, so that the inhibition effect on xanthine oxidase is improved. The lactobacillus rhamnosus LR.M8 can effectively improve the improvement effect of the papaya medicinal and edible homologous plant extract on hyperuricemia, and can repair kidney injury in a human body and regulate uric acid balance. The xanthine oxidase activity inhibition capability of the fermented papaya is obviously improved; the treatment effect on the hyperuricemia is stronger.

This invention belongs to the field of traditional Chinese medicine technology, and provides a compound traditional Chinese medicine extract for lowering uric acid, its preparation, and application. Using hawthorn, astragalus, poria cocos, jujube, and tangerine peel as raw materials, this invention obtains ethanol extract S1 and water extract S2 through ethanol extraction and water extraction. Both S1 and S2 have antioxidant activity, targeting DPPH and ABTS. + The free radicals exhibit significant scavenging capabilities and can effectively inhibit xanthine oxidase activity. Furthermore, S1 and S2 can reduce serum and liver XOD activity in hyperuricemic mice, improve liver and kidney function indicators such as AST, ALT, TP, UREA, SCr, and CysC, and decrease serum uric acid levels in a dose-dependent manner; high doses can lower uric acid levels below normal. The extract of this invention possesses uric acid-lowering, antioxidant, and liver and kidney protective effects, showing good therapeutic effects on hyperuricemia and good protective and preventive effects against liver and kidney damage caused by hyperuricemia.

The invention discloses a pentapeptide LE5 with xanthine oxidase inhibitory activity and a preparation method and application thereof, and belongs to the technical field of small molecule peptides. The amino acid sequence of the pentapeptide LE5 is LGGVE, and the pentapeptide LE5 can be prepared through a solid-phase synthesis method and an enzymolysis method. The pentapeptide LE5 is identified from eucheuma proteolysis liquid and has potential interaction with xanthine oxidase, under the concentration of 0.1 mg / mL, the xanthine oxidase inhibition rate is 60.58%, and compared with goose carnosine (the xanthine oxidase inhibition rate is 36.03%), the xanthine oxidase inhibition rate is remarkably increased (plt; and the compound has higher xanthine oxidase inhibitory activity, and can be used for preparing a preparation for inhibiting xanthine oxidase activity and relieving hyperuricemia.

The invention relates to a uric acid reducing composition and application thereof, and belongs to the technical field of health care products. The uric acid reducing composition disclosed by the invention is prepared from the following components in parts by mass: 4 to 6 parts of sour cherry concentrated powder, 1 to 3 parts of chrysanthemum flower powder, 2 to 4 parts of radix asparagi powder, 1 to 3 parts of herba cepbalanoplosis segeti powder, 1 to 3 parts of vitamin C and 0.5 to 1.5 parts of compound bacterium powder, wherein the total viable count of the compound bacterium powder is 20 billion CFU / g, the compound bacterium powder is composed of TSP05 and TSR332 with the viable count ratio being 1: (1.3-2), the TSP05 is lactobacillus plantarum with the preservation number being CGMCC No.16710, and the TSR332 is lactobacillus reuteri with the preservation number being CGMCC No.15528. The invention further discloses a preparation method of the compound bacterium powder. The uric acid reducing composition has the remarkable effects of reducing uric acid, protecting the liver and kidney and reducing the activity of xanthine oxidase.

The application discloses a pentapeptide VE5 with xanthine oxidase inhibitory activity and a preparation method and application thereof, and belongs to the technical field of small-molecule peptides. The amino acid sequence of the pentapeptide VE5 is VSIVE, and the pentapeptide VE5 can be prepared by a solid-phase synthesis method and an enzymolysis method. The pentapeptide VE5 is identified from a porphyra haitanensis protease hydrolysate, has potential interaction with xanthine oxidase, and has an xanthine oxidase inhibition rate of 67.88% at a concentration of 0.1 mg / mL. Compared with ananeuropeptide (the xanthine oxidase inhibition rate of which is 36.03%), the xanthine oxidase inhibition rate is extremely significantly increased (p<0.001), and the xanthine oxidase inhibitory activity is stronger, so that the pentapeptide VE5 can be used for preparing an xanthine oxidase activity inhibiting preparation and relieving hyperuricemia.

The invention discloses a delinted wormwood extract gel patch as well as a preparation method and application thereof. The preparation method comprises the following steps: mixing delinted wormwood powder and rice meal, and sterilizing to obtain a wormwood matrix; uniformly mixing the wormwood substrate with sterile water and an aspergillus niger seed solution, performing fermentation processing, and drying, crushing and sieving an obtained processed product to obtain processed product powder; extracting the processed product powder by using an ethanol solution to obtain a delinted wormwood extract; or mixing the processed product powder with cassia twig powder, galangal powder, pogostemon cablin powder, dalbergia wood powder, cyperus rotundus powder, radix angelicae powder, pericarpium citri reticulatae powder, salvia miltiorrhiza powder and unprocessed radix aconiti powder, and extracting with an ethanol solution to obtain the processed delinted wormwood extract. The content of polyphenol and flavone in the obtained delinted wormwood extract is increased, the activity of resisting xanthine oxidase is also improved, and the effect of relieving uric acid is remarkably improved. The delinted wormwood extract is prepared into the gel patch, so that the release process is gentle and stable, and the covered joint can be subjected to long-acting and continuous treatment.

The invention relates to medical cold compress gel for improving gout and a preparation method of the medical cold compress gel. The medical cold compress gel comprises the following components in percentage by weight: (1) a cooling matrix material: 0.5-2% of carbomer, 5-15% of glycerol and 3-8% of propylene glycol; (2) natural anti-inflammatory components: 1-3% of a radix scutellariae extract and 0.5-1.5% of asiaticoside; (3) a uric acid inhibitor: 0.2%-1% of apigenin nano-liposome and 0.1%-0.5% of chicoric acid; (4) a transdermal penetration enhancer: 1-3% of azone and 0.5-2% of menthol; and the balance of deionized water. The invention has the following beneficial effects: 1, physical-chemical synergistic effect: red and swollen can be relieved by cold compress, and inflammatory factors such as IL-1beta, TNF-alpha and the like can be inhibited by the active components; 2, targeted inhibition of uric acid: apigenin nano-liposome enhances transdermal absorption and inhibits the activity of xanthine oxidase; 3, the safety is high: the systematic side effects of the traditional medicine are reduced by the natural components;

The present application belongs to the technical field of biological medicine, and provides a cordyceps militaris mycelium extract with uric acid reducing activity, a preparation method and application thereof. 60 The preparation method comprises the following steps: fermenting and culturing a cordyceps militaris strain, collecting the mycelium after fermentation is completed; freezing and drying the mycelium, and then performing Coγ-ray irradiation pretreatment to obtain pretreated mycelium; performing ultrasonic-assisted extraction on the pretreated mycelium to obtain the cordyceps militaris mycelium extract. It is verified through experiments that the cordyceps militaris mycelium extract prepared by the present application belongs to the non-toxic level and has high edible safety. The extract can significantly inhibit xanthine oxidase activity from three levels of in vitro, cells and animals in vivo, can obviously reduce the serum uric acid level of mice and promote the excretion of uric acid in vivo; at the same time, the extract has good regulation and repair effects on relieving liver and kidney damage caused by high uric acid and improving liver lipid metabolism disorder, and has good development value and market application prospect.